首页> 外文OA文献 >PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

【2h】

PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

机译：皮下曲妥珠单抗与静脉曲造珠内菌与静脉胸瘤患者对巴西私人医疗保健系统治疗胸腺胸癌的预算影响模型

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D. Kashiura; P.V. Souza; S.D. Garrido; E. Nardi; M. Alves;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit [J] . Wiebren A.A. Tjalma, Tom Van den Mooter, Tim Mertens, European Journal of Obstetrics, Gynecology and Reproductive Biology: An International Journal . 2018,第期

机译：皮下曲据（Herceptin）与静脉内曲妥珠单抗治疗Her2阳性乳腺癌的患者：瘦营运日保健肿瘤学单位的时间，运动和成本评估研究
2. Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiac toxicity confined to AC-TH: BCIRG 006 study [J] . J.Crown, Eiermann, N.Robert, European Journal of Cancer Supplements . 2006,第2期

机译：与HER-2阳性早期乳腺癌患者（pts）相比，多西紫杉醇，卡铂和曲妥珠单抗（TCH）以及阿霉素/环磷酰胺，多西他赛/曲妥珠单抗（AC-TH）产生的无病生存期（DFS）优于AC-T（DFS）。 EBC），但心脏毒性增加仅限于AC-TH：BCIRG 006研究
3. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer an [J] . Seidman AD, Berry D, Cirrincione C, Journal of Clinical Oncology . 2008,第10期

机译：每周与每3周紫杉醇比较每隔3周进行紫杉醇治疗转移性乳腺癌的随机对照III期试验，对于所有HER-2过表达者都使用曲妥珠单抗，而在HER-2非过表达者中随机分配或不分配曲妥珠单抗：
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Impact of HER-2/neu detection by fluorescence in situ hybridization (FISH) on trastuzumab therapy in the treatment of metastatic breast cancer. [D] . Subongkot, Suphat. 2003

机译：荧光原位杂交（FISH）检测HER-2 / neu对曲妥珠单抗治疗转移性乳腺癌的影响。
6. Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study [O] . Steven Simoens, Arnold G. Vulto, Pieter Dylst 2021

机译：模拟静脉生物仿生曲据与皮下参考曲妥珠氏菌在佐剂Her2阳性乳腺癌中的成本：Belgian案例研究
7. PCN67 - BUDGET IMPACT MODEL OF SUBCUTANEOUS RITUXIMAB COMPARED WITH INTRAVENOUS RITUXIMAB ON THE TREATMENT OF CD-20 POSITIVE NON-HODGKIN LYMPHOMA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM [O] . D. Kashiura, P.V. Souza, A.B. Sá, 2018

机译：与静脉内蓖麻油肢体对巴西私营保健系统CD-20阳性非霍奇金淋巴瘤相比，皮下蓖麻油肢体预算冲击模型

PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

著录项

引文网络

相似文献

相关主题

期刊订阅